Anzeige
Mehr »
Dienstag, 28.10.2025 - Börsentäglich über 12.000 News
Atomkraft feiert Comeback: Uran wird wieder zum strategischen Rohstoff - Anleger stehen Schlange
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3E1W6 | ISIN: AU0000317281 | Ticker-Symbol: AWY0
Tradegate
27.10.25 | 14:14
0,004 Euro
-20,00 % -0,001
Branche
Pharma
Aktienmarkt
AUSTRALIEN
1-Jahres-Chart
PERCHERON THERAPEUTICS LIMITED Chart 1 Jahr
5-Tage-Chart
PERCHERON THERAPEUTICS LIMITED 5-Tage-Chart
RealtimeGeldBriefZeit
0,0010,01021:02
0,0040,00607:39

Aktuelle News zur PERCHERON THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiPERCHERON THERAPEUTICS LIMITED: Results of Annual General Meeting-
MiPERCHERON THERAPEUTICS LIMITED: Annual General Meeting - Management Presentation1
MiPERCHERON THERAPEUTICS LIMITED: Annual General Meeting - Chair's Address-
07.10.Edison Group: Edison Issues Report on Percheron Therapeutics (PER)281London, United Kingdom--(Newsfile Corp. - October 7, 2025) - Edison issues report on Percheron Therapeutics (ASX: PER)Percheron Therapeutics has reported final results from the Phase I dose escalation...
► Artikel lesen
07.10.Percheron Therapeutics - Positive Phase I readout strengthens outlook340Percheron Therapeutics has reported final results from the Phase I dose escalation study of HMBD-002, its monoclonal antibody targeting VISTA, a novel immune checkpoint protein. The data confirmed the...
► Artikel lesen
PERCHERON THERAPEUTICS Aktie jetzt für 0€ handeln
07.10.PERCHERON THERAPEUTICS LIMITED: HMBD-002 Phase I Clinical Trial - Webinar Presentation2
07.10.PERCHERON THERAPEUTICS LIMITED: HMBD-002 Phase I Trial Results7
23.09.PERCHERON THERAPEUTICS LIMITED: Chief Medical Officer and Chief Technology Officer Appointed14
22.09.PERCHERON THERAPEUTICS LIMITED: 2025 Notice of Annual General Meeting3
19.09.Edison Group: Edison Issues Report on Percheron Therapeutics (PER)285London, United Kingdom--(Newsfile Corp. - September 19, 2025) - Edison issues report on Percheron Therapeutics (ASX: PER).Percheron Therapeutics is an emerging immuno-oncology-focused biotech with...
► Artikel lesen
17.09.Percheron Therapeutics - Resetting the narrative with a VISTA focus368Percheron Therapeutics is an emerging immuno-oncology-focused biotech with a business case anchored on its recent in-licensing of HMBD-002, a Phase II-ready, potentially first-in-class anti-VISTA immune...
► Artikel lesen
29.08.Percheron Therapeutics advances first-in-class oncology drug1
29.08.PERCHERON THERAPEUTICS LIMITED: Percheron Receives $1.43m R&D Tax Incentive Rebate-
28.08.PERCHERON THERAPEUTICS LIMITED: Notice of date of AGM and other relevant dates-
28.08.PERCHERON THERAPEUTICS LIMITED: Appendix 4G and Corporate Governance Statement-
28.08.PERCHERON THERAPEUTICS LIMITED: Appendix 4E and Annual Report-
06.08.PERCHERON THERAPEUTICS LIMITED: New Preclinical Data Reported for HMBD-002 in Breast Cancer5
31.07.PERCHERON THERAPEUTICS LIMITED: Quarterly Activities Report and Appendix 4C4
22.07.PERCHERON THERAPEUTICS LIMITED: New Preclinical Data Reported for HMBD-0023
30.06.PERCHERON THERAPEUTICS LIMITED: Change of Director's Interest Notice - Dr James Garner4
Weiter >>
29 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1